Fat cells send message that aids insulin secretion

The body's fat cells help the pancreas do its job of secreting insulin, according to research at Washington University School of Medicine in St. Louis. This previously unrecognized process ultimately could lead to new methods to improve glucose metabolism in type 2 diabetic or insulin-resistant people.

In a study using laboratory mice, published in the November 7, 2007 issue of Cell Metabolism, scientists at the School of Medicine report that fat cells release a protein that aids insulin secretion from pancreatic beta cells, which are the sole source of insulin. The protein is an enzyme that the pancreatic cells themselves produce in only minimal amounts. The enzyme works to enhance glucose-stimulated insulin secretion from pancreatic beta cells.

Insulin helps the body process blood sugar (glucose), and those with type 2 diabetes have a deficiency of insulin or a resistance to its effects. More than 7 million people in the U.S. are living with a diagnosis of type 2 diabetes and many more are undiagnosed.

The researchers assert that the enzyme secreted by fat cells, called Nampt, is an important component of the insulin-secretion pathway. "We think this secretion process allows fat cells to communicate with the pancreas and aid its function," says senior author Shin-ichiro Imai, M.D., Ph.D., assistant professor of medicine and of molecular biology and pharmacology. "I suspect this process could be critical for compensating pancreatic beta cell function in the face of increasing insulin resistance."

The association of type 2 diabetes and insulin resistance with obesity suggests there may be limits to the ability of the process to enhance pancreatic function, according to Imai. "It may be that in some obese individuals a threshold has been reached so that this mechanism no longer provides adequate compensation," he says. "But there may be ways to overcome this threshold."

Interestingly, in 2004 Nampt provoked excitement in the scientific community because it was reported to be a newly discovered fat-derived hormone that worked very much like insulin. That study named the enzyme visfatin. The scientists who made this assertion have since retracted their claim.

In the new study, the Washington University researchers contend that Nampt is not an insulin-like hormone. Instead, their investigation shows it's an enzyme that modulates pancreatic function.

"Our work marks a conceptual breakthrough," Imai says. "Nampt synthesizes a compound in the bloodstream, and when that compound reaches the pancreas it stimulates insulin secretion. This is a surprising mechanism by which a circulating metabolite modulates pancreatic function."

Imai says he believes it's possible that the compound produced by Nampt, called NMN for short, could be used to raise insulin secretion from pancreatic cells and thus help improve the way the body handles sugar. Imai and his group are collaborating with clinical researchers at the University to find out how much NMN is in the blood of normal and diabetic or obese patients. They also hope to initiate clinical trials to test NMN as a therapeutic agent in patients with type 2 diabetes or insulin resistance.

Nampt is actually a widespread enzyme and catalyzes such a fundamental process that most cells of the body have an internal form of it. But, studying mice, the researchers saw that Nampt could be secreted from cells — but only from fat cells. And because Nampt levels are low in pancreatic cells, the pancreas depends on the enzyme secreted from fat and its product, NMN, in the blood.

When pancreatic beta cells absorb enough NMN, it stimulates them to secrete insulin. In the bloodstreams of laboratory mice, NMN was measured at a concentration shown to be sufficient to enhance insulin secretion from pancreatic beta cells. No one had previously known that NMN circulated in the bloodstream.

Mice engineered to have just one instead of two copies of the Nampt gene had a mildly impaired ability to metabolize glucose and had a defect in insulin secretion. The researchers showed that NMN restored normal insulin secretion in these mice.

In conjunction with the Office of Technology Management at the University, Imai has patented the use of Nampt and NMN for the prevention and treatment of metabolic complications, such as type 2 diabetes.

Next, the researchers will try to identify the factors that cause secretion of Nampt from fat cells and the mechanisms by which NMN enhances insulin secretion in the pancreas.

Source: Washington University

Related stories:

Treatment corrects severe insulin imbalance in animal studies
Researchers have used a drug to achieve normal levels of blood sugar in animals genetically engineered to have abnormally high insulin levels. If this approach succeeds in humans, it could become an innovative medicine for children with congenital hyperinsulinism, a rare but potentially devastating genetic disease in which insulin levels become dangerously high.
Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research Forum
Research shows some type 1 adults have beta cells, live complication-free even 50 years after diagnosis
Research findings and innovative approaches offer the promise of new therapies and the potential for cures for adults living with type 1 diabetes, according to researchers at the Juvenile Diabetes Research Foundation's (JDRF's) Global Research Forum in Washington D.C.
Promising advances in islet cell transplants for diabetes
University of Illinois at Chicago researchers have modified the procedure for islet cell transplantation and achieved insulin independence in diabetes patients with fewer but better-functioning pancreatic islet cells.
Discovery of new signal pathway important to diabetes research
Scientists at Karolinska Institutet in Sweden and Miami University have discovered that cells in the pancreas cooperate – signal – in a way hitherto unknown. The discovery can eventually be of significance to the treatment of diabetes.
New mouse model mimics hyperglycemia, aids in diabetes research
UT Southwestern Medical Center researchers have genetically engineered a laboratory mouse in which pancreatic beta cells can regenerate after being induced to die. The new animal model's regenerative ability may provide future insights into improved treatments of diabetes, which affects millions of Americans.
New vaccine approach prevents/reverses diabetes in lab study
Results of study are published in Diabetes, a journal of the American Diabetes Association
Microspheres carrying targeted nucleic acid molecules fabricated in the laboratory have been shown to prevent and even reverse new-onset cases of type 1 diabetes in animal models. The results of these studies were reported by diabetes researchers at the John G. Rangos Sr. Research Center at Children’s Hospital of Pittsburgh of UPMC and Baxter Healthcare Corporation.
Novel mechanisms controlling insulin release and fat deposition discovered
Scientists at the Swedish medical university Karolinska Institutet have in two recent studies shown that a receptor called ALK7 plays important roles in the regulation of body fat deposition as well as the release of insulin from beta-cells in the pancreas. These findings have implications for the development of treatments against diabetes and obesity.
Studies test new approaches to islet transplantation
Researchers from 11 medical centers in the United States, Canada, Sweden, and Norway have begun testing new approaches to transplanting clusters of insulin-producing islets in adults with difficult-to-control type 1 diabetes. The clinical studies, funded by the National Institutes of Health (NIH), will determine whether changes to current methods of islet transplantation lead to improved, long-lasting control of blood glucose with fewer side effects.

News discussion:

Medicine & Health news